In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system

FEBS Journal

Volumn 280, Issue 14, 2013, Pages 3376-3388

  Bari, Monica ^a   Battista, Natalia ^b,c   Valenza, Marta ^d   Mastrangelo, Nicolina ^a   Malaponti, Marinella ^a   Catanzaro, Giuseppina ^b,c   Centonze, Diego ^a,c   Finazzi Agrò, Alessandro ^e   Cattaneo, Elena ^d   Maccarrone, Mauro ^c,e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

endocannabinoid; fatty acid amide hydrolase (FAAH); Huntington's disease; lymphocyte; R6 2 mice

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; HYDROLASE; LIPOPROTEIN LIPASE; N ACYL PHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL CLONE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; FLUORESCENCE MICROSCOPY; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING;

ENDOCANNABINOID; FATTY ACID AMIDE HYDROLASE (FAAH); HUNTINGTON'S DISEASE; LYMPHOCYTE; R6/2 MICE;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CELL LINE; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; HUNTINGTON DISEASE; KINETICS; LYMPHOCYTES; MICE; MICE, TRANSGENIC; NEOSTRIATUM; RATS;

ANIMALIA; MUS; RATTUS;

EID: 84879990830     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12329     Document Type: Article

References (58)

1. Zuccato C, Valenza M, &, Cattaneo E, (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90, 905-981.
2. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
3. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, et al,. (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78, 690-695.
4. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, et al,. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
5. Cattaneo E, &, Conti L, (1998) Generation and characterization of embryonic striatal conditionally immortalized ST14A cells. J Neurosci Res 53, 223-234.
6. Hovakimyan M, Weinreich K, Haas SJP, Cattaneo E, Rolfs A, &, Wree A, (2008) In vitro characterization of embryionic ST14A-cells. Int J Neurosci 118, 1489-1501.
7. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, Kooperberg C, Olson JM, &, Cattaneo E, (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11, 1953-1965.
8. Hanus LO, &, Mechoulam R, (2010) Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem 17, 1341-1359.
9. Howlett AC, Blume LC, &, Dalton GD, (2010) CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem 17, 1382-1393.
10. Patel KD, Davison JS, Pittman QJ, &, Sharkey KA, (2010) Cannabinoid CB(2) receptors in health and disease. Curr Med Chem 17, 1393-1410.
11. Di Marzo V, &, De Petrocellis L, (2010) Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 17, 1430-1449.
12. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agrò A, et al,. (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11, 152-159.
13. Okamoto Y, Morishita J, Tsuboi K, Tonai T, &, Ueda N, (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279, 5298-5305.
14. McKinney MK, &, Cravatt BF, (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74, 411-432.
15. Fezza F, De Simone C, Amadio D, &, Maccarrone M, (2008) Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 49, 101-132.
16. Min R, Di Marzo V, &, Mansvelder HD, (2010) DAG lipase involvement in depolarization-induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand? Neuroscientist 16, 608-613.
17. Ligresti A, Petrosino S, &, Di Marzo V, (2009) From endocannabinoid profiling to 'endocannabinoid therapeutics'. Curr Opin Chem Biol 13, 321-331.
18. Katona I, &, Freund TF, (2008) Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14, 923-930.
19. Di Filippo M, Picconi B, Tozzi A, Ghiglieri V, Rossi A, &, Calabresi P, (2008) The endocannabinoid system in Parkinson's disease. Curr Pharm Des 14, 2337-2347.
20. Ruiz-Valdepeñas L, Benito C, Tolõn RM, Martínez Orgado JA, &, Romero J, (2010) The endocannabinoid system and amyloid-related diseases. Exp Neurol 224, 66-73.
21. Rossi S, Bernardi G, &, Centonze D, (2010) The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 224, 92-102.
22. Bisogno T, Martire A, Petrosino S, Popoli P, &, Di Marzo V, (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem Int 52, 307-313.
23. Lastres-Becker I, De Miguel R, &, Fernandez-Ruiz JJ, (2003) The endocannabinoid system and Huntington's disease. Curr Drug Targets CNS Neurol Disord 2, 335-347.
24. Fernandez-Ruiz J, Gonzalez S, Romero J, &, Ramos JA, (2005) Cannabinoids in neurodegeneration and neuroprotection. In Cannabinoids as Therapeutics (, Mechoulam R, ed.), pp. 79-109. Birkhauser Verlag, Berlin.
25. Pazos MR, Sagredo O, &, Fernández-Ruiz J, (2008) The endocannabinoid system in Huntington's disease. Curr Pharm Des 14, 2317-2325.
26. Scotter EL, Goodfellow CE, Graham ES, Dragunow M, &, Glass M, (2010) Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol 160, 747-761.
27. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, et al,. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119-136.
28. Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, et al,. (2013) Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. Eur J Neurosci 37, 429-440.
29. Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, &, Calabresi P, (2005) Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered GABA transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 57, 1583-1589.
30. Cepeda C, Cummings DM, Hickey MA, Kleiman-Weiner M, Chen JY, Watson JB, &, Levine MS, (2010) Rescuing the corticostriatal synaptic disconnection in the R6/2 mouse model of Huntington's disease: exercise, adenosine receptors and ampakines. PLoS Curr 2, doi: 10.1371/currents.RRN1182.
31. Grigorenko E, Kittler J, Clayton C, Wallace D, Zhuang S, Bridges D, Bundey S, Boon A, Pagget C, Hayashizaki S, et al,. (2002) Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem Phys Lipids 121, 257-266.
32. Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, et al,. (2011) Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One 6, e22966. doi: 10.1371/journal.pone.0022966.
33. Cattaneo E, Zuccato C, &, Tartari M, (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 6, 919-930.
34. De Chiara V, Angelucci F, Rossi S, Musella A, Cavasinni F, Cantarella C, Mataluni G, Sacchetti L, Napolitano F, Castelli M, et al,. (2010) Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum. J Neurosci 30, 8127-8137.
35. Valenza M, &, Cattaneo E, (2011) Emerging roles for cholesterol in Huntington's disease. Trends Neurosci 34, 474-486.
36. Maccarrone M, De Chiara V, Gasperi V, Viscomi MT, Rossi S, Oddi S, Molinari M, Musella A, Finazzi-Agro A, &, Centonze D, (2009) Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. J Neurochem 109, 371-381.
37. Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, Martire A, Potenza RL, Ferraro L, Tanganelli S, Watanabe M, et al,. (2012) Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol Dis 45, 983-991.
38. Curtis A, Mitchell I, Patel S, Ives N, &, Rickards H, (2009) A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 24, 2254-2259.
39. Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolõn RM, Mechoulam R, Brouillet E, et al,. (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57, 1154-1167.
40. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, et al,. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132, 3152-3164.
41. Ide K, Nukina N, Masuda N, Goto J, &, Kanazawa I, (1995) Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem Biophys Res Commun 209, 1119-1125.
42. Varani K, Abbracchio MP, Cannella M, Cislaghi G, Giallonardo P, Mariotti C, Cattabriga E, Cattabeni F, Borea PA, Squitieri F, et al,. (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 17, 2148-2150.
43. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, et al,. (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 102, 11023-11028.
44. Battista N, Bari M, Tarditi A, Mariotti C, Bachoud-Lévi A, Zuccato C, Finazzi-Agrò A, Genitrini S, Peschanski M, Di Donato S, et al,. (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 27, 108-116.
45. Pertwee RG, (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17, 1360-1381.
46. Bari M, Tedesco M, Battista N, Pasquariello N, Pucci M, Gasperi V, Scaldaferri ML, Farini D, De Felici M, &, Maccarrone M, (2011) Characterization of the endocannabinoid system in mouse embryonic stem cells. Stem Cells Dev 20, 139-147.
47. Simon GM, &, Cravatt BF, (2010) Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol BioSyst 8, 1411-1418.
48. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, et al,. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13, 951-957.
49. Gattinoni S, De Simone C, Dallavalle S, Fezza F, Nannei R, Amadio D, Minetti P, Quattrociocchi G, Caprioli A, Borsini F, et al,. (2010) Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system. Chem Med Chem 5, 357-360.
50. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, &, Finazzi-Agrò A, (2000) Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355, 1326-1329.
51. Oddi S, Bari M, Battista N, Barsacchi D, Cozzani I, &, Maccarrone M, (2005) Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell Mol Life Sci 62, 386-395.
52. Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, &, Piomelli D, (2000) Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol 408, 161-168.
53. Francavilla F, Battista N, Barbonetti A, Vassallo MR, Rapino C, Antonangelo C, Pasquariello N, Catanzaro G, Barboni B, &, Maccarrone M, (2009) Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. Endocrinology 150, 4692-4700.
54. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, &, Pertwee RG, (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132, 631-640.
55. Fezza F, Gasperi V, Mazzei C, &, Maccarrone M, (2005) Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) activity. Anal Biochem 339, 113-120.
56. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, et al,. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid knockout in the brain. J Cell Biol 163, 463-468.
57. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, &, Piomelli D, (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99, 10819-10824 (Erratum in: Proc Natl Acad Sci USA 15, 13961).
58. Pasquariello N, Catanzaro G, Marzano V, Amadio D, Barcaroli D, Oddi S, Federici G, Urbani A, Finazzi Agrò A, &, Maccarrone M, (2009) Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem 284, 29413-29426. Ricerca